The use of growth factors and cytokines to treat opportunistic infections in HIV-1 disease
Anthony Jaworowski A B , Clare L.V. Maslin A and Steven L. Wesselingh A
+ Author Affiliations
- Author Affiliations
A AIDS Pathogenesis and Clinical Research Program, The Burnet Institute for Medical Research and Public Health, GPO Box 2284, Melbourne, Vic. 3001, Australia; and Department of Medicine, Monash University, Melbourne, Australia.
B Author for correspondence; email: anthonyj@burnet.edu.au
Sexual Health 1(3) 161-174 https://doi.org/10.1071/SH03022
Submitted: 8 December 2003 Accepted: 29 July 2004 Published: 23 September 2004
Abstract
The success of highly active antiretroviral therapy (HAART) in reducing AIDS-related mortality means that in regions where HAART is available, HIV infection may now be regarded as a chronic disease. However the inability of HAART to eliminate HIV-1 from various anatomical and cellular reservoirs within the body means that HIV-infected individuals require life-long treatment with therapy that can have significant side effects. Management of HIV disease is therefore increasingly focused on drug-related toxicities and the improvement of current HAART regimens. Here we review the potential use of immunomodulatory cytokines to directly or indirectly stimulate the mononuclear phagocyte system as adjuncts to current HIV treatment as well as their use in the management of opportunistic infections in individuals who develop immunodeficiency.
We argue that cytokines, which stimulate mononuclear phagocyte activity against opportunistic pathogens, may be useful for the treatment of individuals who develop recurrent opportunistic infections. Cytokines may act synergistically with antimicrobial agents to improve outcomes, which is of particular importance since recurrent infections frequently result in resistance to standard antimicrobial treatments. Before their use can be advocated however, given their toxicity and significant cost, the potential benefits of cytokines must be demonstrated in larger clinical trials.
References
[1] Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991; 4(8): 770–6.
| PubMed |
[2] Sax PE. Opportunistic infections in HIV disease: down but not out. Infect Dis Clin North Am 2001; 15(2): 433–55.
| PubMed |
[3] Clerici M, Shearer GM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14(3): 107–11.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[4] Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15(12): 575–81.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[5] Maggi E, Mazzetti M, Ravina A, Annunziato F, de Carli M, Piccinni MP, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 1994; 265(5169): 244–8.
| PubMed |
[6] Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994; 265(5169): 248–52.
| PubMed |
[7] Chehimi J, Starr SE, Frank I, D'Andrea A, Ma X, MacGregor RR, et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994; 179(4): 1361–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[8] Havlir DV, Schrier RD, Torriani FJ, Chervenak K, Hwang JY, Boom WH. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis 2000; 182(6): 1658–63.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[9] Vecchiet J, Dalessandro M, Travasi F, Falasca K, Di Iorio A, Schiavone C, et al. Interleukin-4 and interferon-gamma production during HIV-1 infection and changes induced by antiretroviral therapy. Int J Immunopathol Pharmacol 2003; 16(2): 157–66.
| PubMed |
[10] Taoufik Y, Peguillet I, de Goer MG, Lambert M, Gubler B, Trylesinski A, et al. Effect of highly active antiretroviral therapy on expression of interleukin-10 and interleukin-12 in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26(4): 303–4.
| PubMed |
[11] Alfonzo M, Blanc D, Troadec C, Eliaszewicz M, Gonzalez G, Scott-Algara D. Partial restoration of cytokine profile despite reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients during highly active antiretroviral treatment. Scand J Immunol 2003; 57(4): 375–83.
| PubMed |
[12] Chougnet C, Fowke KR, Mueller BU, Smith S, Zuckerman J, Jankelevitch S, et al. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. AIDS 1998; 12(18): 2397–406.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[13] Chougnet C, Jankelevich S, Fowke K, Liewehr D, Steinberg SM, Mueller BU, et al. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. J Infect Dis 2001; 184(2): 201–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[14] Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, et al. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J Immunol 2002; 168(11): 5764–70.
| PubMed |
[15] Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest 2002; 122(2): 597–602.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[16] Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277(5322): 112–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[17] Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998; 352(9135): 1194–5.
| PubMed |
[18] Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351(9117): 1682–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[19] Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179(2): 329–36.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[20] Pontesilli O, Kerkhof-Garde S, Notermans DW, Foudraine NA, Roos MT, Klein MR, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180(1): 76–86.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[21] Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178(1): 70–9.
| PubMed |
[22] Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003; 17(4): 169–77.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[23] Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17(13): 1925–32.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[24] Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000; 30(2): 256–60.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[25] Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001; 12(9): 555–62.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[26] Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 2001; 6(1): 14–20.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[27] Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354(9184): 1112–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[28] Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003; 5(1): 36–43.
| PubMed |
[29] Heath KV, Montaner JS, Bondy G, Singer J, O’Shaughnessy MV, Hogg RS. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets 2003; 4(1): 13–22.
| PubMed |
[30] Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003; 2(8): 624–34.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[31] Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103(9): 3282–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[32] Pett SL, Emery S. Immunomodulators as adjunctive therapy for HIV-1 infection. J Clin Virol 2001; 22(3): 289–95.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[33] Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23(2): 198–220.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[34] Gherardi MM, Ramirez JC, Esteban M. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol 2001; 16(2): 655–67.
| PubMed |
[35] Imami N, Hardy G, Pires A, Burton C, Pido-Lopez J, Mela C, et al. Immune reconstitution in HIV-1-infected patients. Curr Opin Investig Drugs 2002; 3(8): 1138–45.
| PubMed |
[36] Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003; 3(3): 285–301.
| PubMed |
[37] Hooker A, James D. The glycosylation heterogeneity of recombinant human IFN-gamma. J Interferon Cytokine Res 1998; 18(5): 287–95.
| PubMed |
[38] Murray HW. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 1988; 108(4): 595–608.
| PubMed |
[39] Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136(7): 2348–57.
| PubMed |
[40] Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001; 13(4): 458–64.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[41] Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259(5102): 1739–42.
| PubMed |
[42] Swihart K, Fruth U, Messmer N, Hug K, Behin R, Huang S, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med 1995; 181(3): 961–71.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[43] Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259(5102): 1742–5.
| PubMed |
[44] Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335(26): 1956–61.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[45] Pierre-Audigier C, Jouanguy E, Lamhamedi S, Altare F, Rauzier J, Vincent V, et al. Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency. Clin Infect Dis 1997; 24(5): 982–4.
| PubMed |
[46] Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335(26): 1941–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[47] Jouanguy E, Lamhamedi-Cherradi S, Lammas D, Dorman SE, Fondaneche MC, Dupuis S, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999; 21(4): 370–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[48] Dupuis S, Doffinger R, Picard C, Fieschi C, Altare F, Jouanguy E, et al. Human interferon-gamma-mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol Rev 2000; 178 129–37.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[49] Murray HW, Rubin BY, Masur H, Roberts RB. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310(14): 883–9.
| PubMed |
[50] Murray HW, Hillman JK, Rubin BY, Kelly CD, Jacobs JL, Tyler LW, et al. Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production. N Engl J Med 1985; 313(24): 1504–10.
| PubMed |
[51] Westby M, Marriott JB, Guckian M, Cookson S, Hay P, Dalgleish AG. Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction. Clin Exp Immunol 1998; 111(2): 257–63.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[52] Bailer RT, Holloway A, Sun J, Margolick JB, Martin M, Kostman J, et al. IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. J Immunol 1999; 162(12): 7534–42.
| PubMed |
[53] Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, et al. Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood 2002; 99(7): 2505–11.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[54] Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Bulk cytokine production versus frequency of cytokine-producing cells in HIV1 infection before and during HAART. Clin Immunol 2000; 97(2): 162–70.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[55] Sousa AE, Victorino RM. Single-cell analysis of lymphokine imbalance in asymptomatic HIV-1 infection: evidence for a major alteration within the CD8+ T cell subset. Clin Exp Immunol 1998; 112(2): 294–302.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[56] Helms T, Boehm BO, Asaad RJ, Trezza RP, Lehmann PV, Tary-Lehmann M. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol 2000; 164(7): 3723–32.
| PubMed |
[57] Ostrowski MA, Gu JX, Kovacs C, Freedman J, Luscher MA, MacDonald KS. Quantitative and qualitative assessment of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cell immunity to gag in HIV-1-infected individuals with differential disease progression: reciprocal interferon-gamma and interleukin-10 responses. J Infect Dis 2001; 184(10): 1268–78.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[58] Fournier S, Rabian C, Alberti C, Carmagnat MV, Garin JF, Charron D, et al. Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis 2001; 183(11): 1586–91.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[59] Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000; 14(7): 761–70.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[60] Havlir DV, Torriani FJ, Schrier RD, Huang JY, Lederman MM, Chervenak KA, et al. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol 2001; 39(1): 298–303.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[61] Murray HW. Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 1994; 97(5): 459–67.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[62] Shearer WT, Kline MW, Abramson SL, Fenton T, Starr SE, Douglas SD. Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211). Clin Diagn Lab Immunol 1999; 6(3): 311–5.
| PubMed |
[63] Riddell LA, Pinching AJ, Hill S, Ng TT, Arbe E, Lapham GP, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001; 17(9): 789–97.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[64] Squires KE, Murphy WF, Madoff LC, Murray HW. Interferon-gamma and Mycobacterium avium-intracellulare infection. J Infect Dis 1989; 159(3): 599–600.
| PubMed |
[65] Squires KE, Brown ST, Armstrong D, Murphy WF, Murray HW. Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS. J Infect Dis 1992; 166(3): 686–7.
| PubMed |
[66] Lortholary O, Mechali D, Christiaens D, Gougerot Pocidalo M, Brandely M, et al. Interferon-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS. Rev Infect Dis 1990; 12(2): 370–1.
| PubMed |
[67] Lafeuillade A, Quilichini R, Dhiver C, Mary C, Gastaut JA. The need for new therapeutic approaches in visceral leishmaniasis during HIV infection. Postgrad Med J 1990; 66(779): 789–90.
| PubMed |
[68] de Gorgolas M, Castrillo JM, Fernandez Guerrero ML. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma. Clin Infect Dis 1993; 17(1): 56–8.
| PubMed |
[69] Bodasing N, Seaton RA, Shankland GS, Pithie A. Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother 2002; 50(5): 765–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[70] Poli G, Biswas P, Fauci AS. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res 1994; 24(2-3): 221–33.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[71] Bodi I, Abraham AA, Kimmel PL. Macrophages in human immunodeficiency virus-associated kidney diseases. Am J Kidney Dis 1994; 24(5): 762–7.
| PubMed |
[72] Liu QN, Reddy S, Sayre JW, Pop V, Graves MC, Fiala M. Essential role of HIV type 1-infected and cyclooxygenase 2-activated macrophages and T cells in HIV type 1 myocarditis. AIDS Res Hum Retroviruses 2001; 17(15): 1423–33.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[73] Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67(1): 37–45.
| PubMed |
[74] Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A. Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 1998; 26(2): 100–3.
| PubMed |
[75] Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995; 155(18): 1965–70.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[76] Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997; 157(16): 1825–31.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[77] Tumbarello M, Tacconelli E, Donati KG, Citton R, Leone F, Spanu T, et al. HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr 2000; 23(2): 145–51.
| PubMed |
[78] Levine JD, Allan JD, Tessitore JH, Falcone N, Galasso F, Israel RJ, et al. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood 1991; 78(12): 3148–54.
| PubMed |
[79] Manfredi R, Mastroianni A, Coronado O, Chiodo F. Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in leukopenic patients with advanced HIV disease. J Chemother 1996; 8(3): 214–20.
| PubMed |
[80] Kimura S, Matsuda J, Ikematsu S, Miyazono K, Ito A, Nakahata T, et al. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990; 4(12): 1251–5.
| PubMed |
[81] Kaczmarski RS, Pozniak A, Lakhani A, Harvey E, Mufti GJ. A pilot study of low-dose recombinant human granulocyte-macrophage colony-stimulating factor in chronic neutropenia. Br J Haematol 1993; 84(2): 338–40.
| PubMed |
[82] Dubreuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R, et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 2000; 65(5): 337–43.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[83] Mitsuyasu R. Prevention of bacterial infections in patients with advanced HIV infection. AIDS 1999; 13 S19–23.
[84] Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998; 104(1): 48–55.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[85] Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12(1): 65–74.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[86] Hermans P, Rozenbaum W, Jou A, Castelli F, Borleffs J, Gray S, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS 1996; 10(14): 1627–33.
| PubMed |
[87] Newell M, Goldstein D, Milliken S, Lewis C, Hoy J, Thomson B, et al. Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin’s lymphoma. Ann Oncol 1996; 7(10): 1029–36.
| PubMed |
[88] Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991; 9(6): 929–40.
| PubMed |
[89] Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986; 78(5): 1220–8.
| PubMed |
[90] Smith PD, Lamerson CL, Wong HL, Wahl LM, Wahl SM. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J Immunol 1990; 144(10): 3829–34.
| PubMed |
[91] Smith PD, Lamerson CL, Banks SM, Saini SS, Wahl LM, Calderone RA, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis 1990; 161(5): 999–1005.
| PubMed |
[92] Coleman DL, Chodakewitz JA, Bartiss AH, Mellors JW. Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood 1988; 72(2): 573–8.
| PubMed |
[93] Bober LA, Grace MJ, Pugliese-Sivo C, Rojas-Triana A, Sullivan LM, Narula SK. The effects of colony stimulating factors on human monocyte cell function. Int J Immunopharmacol 1995; 17(5): 385–92.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[94] Eischen A, Vincent F, Bergerat JP, Louis B, Faradji A, Bohbot A, et al. Long term cultures of human monocytes in vitro. Impact of GM-CSF on survival and differentiation. J Immunol Methods 1991; 143(2): 209–21.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[95] Robin G, Markovich S, Athamna A, Keisari Y. Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 1991; 10(4): 257–63.
| PubMed |
[96] Burgess AW, Begley CG, Johnson GR, Lopez AF, Williamson DJ, Mermod JJ, et al. Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood 1987; 69(1): 43–51.
| PubMed |
[97] Fleischmann J, Golde DW, Weisbart RH, Gasson JC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986; 68(3): 708–11.
| PubMed |
[98] Handman E, Burgess AW. Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 1979; 122(3): 1134–7.
| PubMed |
[99] Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 1992; 22(6): 1447–54.
| PubMed |
[100] Richardson MD, Brownlie CE, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 1992; 30(6): 433–41.
| PubMed |
[101] Capsoni F, Bonara P, Minonzio F, Ongari AM, Colombo G, Rizzardi GP, et al. The effect of cytokines on human neutrophil Fc receptor-mediated phagocytosis. J Clin Lab Immunol 1991; 34(3): 115–24.
| PubMed |
[102] Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990; 48(1): 67–73.
| PubMed |
[103] Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996; 34(1): 63–9.
| PubMed |
[104] Reed SG, Nathan CF, Pihl DL, Rodricks P, Shanebeck K, Conlon PJ, et al. Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma. J Exp Med 1987; 166(6): 1734–46.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[105] Newman SL, Gootee L. Colony-stimulating factors activate human macrophages to inhibit intracellular growth of Histoplasma capsulatum yeasts. Infect Immun 1992; 60(11): 4593–7.
| PubMed |
[106] Baldwin GC, Gasson JC, Quan SG, Fleischmann J, Weisbart R, Oette D, et al. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 1988; 85(8): 2763–6.
| PubMed |
[107] Capsoni F, Minonzio F, Ongari AM, Rizzardi GP, Lazzarin A, Zanussi C. Monocyte-derived macrophage function in HIV-infected subjects: in vitro modulation by rIFN-gamma and rGM-CSF. Clin Immunol Immunopathol 1992; 62(2): 176–82.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[108] Bermudez LE, Kemper CA, Deresinski SC. Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF. Biotherapy 1994; 8(2): 135–42.
| PubMed |
[109] Kedzierska K, Mak J, Mijch A, Cooke I, Rainbird M, Roberts S, et al. Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo. J Infect Dis 2000; 181(1): 390–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[110] Perno CF, Cooney DA, Gao WY, Hao Z, Johns DG, Foli A, et al. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992; 80(4): 995–1003.
| PubMed |
[111] Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91(12): 5592–6.
| PubMed |
[112] Berclaz PY, Shibata Y, Whitsett JA, Trapnell BC. GM-CSF, via PU.1, regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamma -mediated molecular connection between innate and adaptive immunity in the lung. Blood 2002; 100(12): 4193–200.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[113] Berclaz PY, Zsengeller Z, Shibata Y, Otake K, Strasbaugh S, Whitsett JA, et al. Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1. J Immunol 2002; 169(11): 6332–42.
| PubMed |
[114] Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001; 15(4): 557–67.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[115] Eichbaum Q, Heney D, Raveh D, Chung M, Davidson M, Epstein J, et al. Murine macrophage mannose receptor promoter is regulated by the transcription factors PU.1 and SP1. Blood 1997; 90(10): 4135–43.
| PubMed |
[116] Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8(9): 891–6.
| PubMed |
[117] Koziel H, Eichbaum Q, Kruskal BA, Pinkston P, Rogers RA, Armstrong MY, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998; 102(7): 1332–44.
| PubMed |
[118] Chroneos Z, Shepherd VL. Differential regulation of the mannose and SP-A receptors on macrophages. Am J Physiol 1995; 269(6 Pt 1): L721–6.
| PubMed |
[119] Jones T, Stern A, Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994; 13 S47–53.
| PubMed |
[120] Skowron G, Stein D, Drusano G, Melbourne K, Bilello J, Mikolich D, et al. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial. J Infect Dis 1999; 180(4): 1064–71.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[121] Barbaro G, Di Lorenzo G, Grisorio B, Soldini M, Barbarini G. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study. AIDS 1997; 11(12): 1453–61.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[122] Brites C, Gilbert MJ, Pedral-Sampaio D, Bahia F, Pedroso C, Alcantara AP, et al. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS. J Infect Dis 2000; 182(5): 1531–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[123] Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, et al. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group. AIDS 2000; 14(4): 387–95.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[124] Kemper CA, Bermudez LE, Deresinski SC. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor. J Infect Dis 1998; 177(4): 914–20.
| PubMed |
[125] Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, Chen IS. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988; 241(4873): 1673–5.
| PubMed |
[126] Perno CF, Yarchoan R, Cooney DA, Hartman NR, Webb DS, Hao Z, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2'3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989; 169(3): 933–51.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[127] Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998; 72(9): 7642–7.
| PubMed |
[128] Kedzierska K, Maerz A, Warby T, Jaworowski A, Chan H, Mak J, et al. Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages. AIDS 2000; 14(12): 1739–48.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[129] Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, Takemori T. Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. AIDS Res Hum Retroviruses 1995; 11(9): 1031–8.
| PubMed |
[130] Di Marzio P, Tse J, Landau NR. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses 1998; 14(2): 129–38.
| PubMed |
[131] Wesselingh SL, Thompson KA. Immunopathogenesis of HIV-associated dementia. Curr Opin Neurol 2001; 14(3): 375–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[132] McLay RN, Kimura M, Banks WA, Kastin AJ. Granulocyte-macrophage colony-stimulating factor crosses the blood–brain and blood–spinal cord barriers. Brain 1997; 120(Pt 11): 2083–91.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[133] Si Q, Cosenza M, Zhao ML, Goldstein H, Lee SC. GM-CSF and M-CSF modulate beta-chemokine and HIV-1 expression in microglia. Glia 2002; 39(2): 174–83.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[134] Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999; 155(5): 1599–611.
| PubMed |
[135] Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84(12): 4008–27.
| PubMed |
[136] Chehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994; 14(3): 149–61.
| PubMed |
[137] D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176(5): 1387–98.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[138] Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13 251–76.
| PubMed |
[139] Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3(2): 133–46.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[140] Marshall JD, Robertson SE, Trinchieri G, Chehimi J. Priming with IL-4 and IL-13 during HIV-1 infection restores in vitro IL-12 production by mononuclear cells of HIV-infected patients. J Immunol 1997; 159(11): 5705–14.
| PubMed |
[141] Denis M, Ghadirian E. Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. AIDS Res Hum Retroviruses 1994; 10(12): 1619–27.
| PubMed |
[142] Gazzinelli RT, Bala S, Stevens R, Baseler M, Wahl L, Kovacs J, et al. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. J Immunol 1995; 155(3): 1565–74.
| PubMed |
[143] Daftarian MP, Diaz-Mitoma F, Creery WD, Cameron W, Kumar A. Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus-infected individuals is associated with altered proliferative responses to recall antigens. Clin Diagn Lab Immunol 1995; 2(6): 712–8.
| PubMed |
[144] Chougnet C, Wynn TA, Clerici M, Landay AL, Kessler HA, Rusnak J, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis 1996; 174(1): 46–53.
| PubMed |
[145] Zanussi S, D’Andrea M, Simonelli C, Trabattoni D, Bortolin MT, Caggiari L, et al. The effects of CD40 ligation on peripheral blood mononuclear cell interleukin-12 and interleukin-15 production and on monocyte CD14 surface antigen expression in human immunodeficiency virus-positive patients. Scand J Immunol 1999; 49(3): 286–92.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[146] Parayath KE, Harrison TS, Levitz SM. Effect of interleukin (IL)-15 priming on IL-12 and interferon-gamma production by pathogen-stimulated peripheral blood mononuclear cells from human immunodeficiency virus-seropositive and -seronegative donors. J Infect Dis 2000; 181(2): 733–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[147] Bocchino M, Ledru E, Debord T, Gougeon ML. Increased priming for interleukin-12 and tumour necrosis factor alpha in CD64 monocytes in HIV infection: modulation by cytokines and therapy. AIDS 2001; 15(10): 1213–23.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[148] Chehimi J, Starr SE, Frank I, Rengaraju M, Jackson SJ, Llanes C, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175(3): 789–96.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[149] Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993; 262(5140): 1721–4.
| PubMed |
[150] Newman GW, Guarnaccia JR, Vance EA, Wu JY, Remold HG, Kazanjian PH. Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to Mycobacterium avium. AIDS 1994; 8(10): 1413–9.
| PubMed |
[151] Matsuo R, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection. J Leukoc Biol 1996; 59(5): 623–30.
| PubMed |
[152] Orange JS, Wolf SF, Biron CA. Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol 1994; 152(3): 1253–64.
| PubMed |
[153] Gazzinelli RT, Giese NA, Morse HC. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994; 180(6): 2199–208.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[154] Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100–500 CD4 cells/microL. J Infect Dis 2000; 182(4): 1070–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[155] Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, et al. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 2002; 16(8): 1147–54.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[156] Foli A, Saville MW, Baseler MW, Yarchoan R. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication. Blood 1995; 85(8): 2114–23.
| PubMed |
[157] Perales MA, Skolnik PR, Lieberman J. Effect of interleukin 12 on in vitro HIV type 1 replication depends on clinical stage. AIDS Res Hum Retroviruses 1996; 12(8): 659–68.
| PubMed |
[158] Akridge RE, Reed SG. Interleukin-12 decreases human immunodeficiency virus type 1 replication in human macrophage cultures reconstituted with autologous peripheral blood mononuclear cells. J Infect Dis 1996; 173(3): 559–64.
| PubMed |
[159] Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90(7): 2541–8.
| PubMed |
[160] Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003; 3 7.
| PubMed |
[161] Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5(8): 919–23.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[162] Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284(5421): 1835–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[163] Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71(4): 565–81.
| PubMed |
[164] Soumelis V, Scott I, Gheyas F, Bouhour D, Cozon G, Cotte L, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98(4): 906–12.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[165] Donaghy H, Pozniak A, Gazzard B, Qazi N, Gilmour J, Gotch F, et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001; 98(8): 2574–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[166] Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 166(4): 2291–5.
| PubMed |
[167] Soumelis V, Scott I, Liu YJ, Levy J. Natural type 1 interferon producing cells in HIV infection. Hum Immunol 2002; 63(12): 1206–12.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[168] Siegal FP, Fitzgerald-Bocarsly P, Holland BK, Shodell M. Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS 2001; 15(13): 1603–12.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[169] Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001; 98(10): 3016–21.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[170] Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168(9): 4796–801.
| PubMed |
[171] Neau D, Trimoulet P, Winnock M, Rullier A, Le Bail B, Lacoste D, et al. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003; 36(12): 1564–71.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[172] Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17(7): 1023–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[173] Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15(16): 2149–55.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[174] Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS 2001; 15(14): 1783–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[175] Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 2002; 16(15): 2083–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[176] Haas DW, Lavelle J, Nadler JP, Greenberg SB, Frame P, Mustafa N, et al. A randomized trial of interferon alpha therapy for HIV type 1 infection. AIDS Res Hum Retroviruses 2000; 16(3): 183–90.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[177] Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(4): 731–46.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[178] Debien C, De Chouly De Lenclave MB, Foutrein P, Bailly D. Alpha-interferon and mental disorders. Encephale 2001; 27(4): 308–17.
| PubMed |
[179] Bonder CS, Davies KV, Liu X, Hertzog PJ, Woodcock JM, Finlay-Jones JJ, et al. Endogenous interferon-alpha production by differentiating human monocytes regulates expression and function of the IL-2/IL-4 receptor gamma chain. Cytokine 2002; 17(4): 187–96.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
